{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:02:49Z","timestamp":1790128969245,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011643","name":"Blavatnik Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bbrc.2021.10.036","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T13:43:34Z","timestamp":1634564614000},"page":"100-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK\/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model"],"prefix":"10.1016","volume":"582","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-5900","authenticated-orcid":false,"given":"Keren","family":"Oved","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Zennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-2617","authenticated-orcid":false,"given":"Orly","family":"Dorot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane N.","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bremond-Gignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8488-8710","authenticated-orcid":false,"given":"Edward","family":"Pichinuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4019-5418","authenticated-orcid":false,"given":"Daniel","family":"Aberdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.10.036_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/bjo.83.6.723","article-title":"PAX6 expression in the developing human eye","volume":"83","author":"Nishina","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.bbrc.2021.10.036_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.survophthal.2017.09.004","article-title":"The genetics of congenital aniridia - a guide for the ophthalmologist","volume":"63","author":"Landsend","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.bbrc.2021.10.036_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ophtha.2019.09.034","article-title":"PAX6 mutational status determines aniridia-associated keratopathy phenotype","volume":"127","author":"Lagali","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bbrc.2021.10.036_bib4","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1167\/iovs.13-11780","article-title":"In\u00a0vivo morphology of the limbal palisades of vogt correlates with progressive stem cell deficiency in aniridia-related keratopathy","volume":"54","author":"Lagali","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bbrc.2021.10.036_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/08820538.2013.825293","article-title":"A\u00a0review of the clinical and genetic aspects of aniridia","volume":"28","author":"Lee","year":"2013","journal-title":"Semin. Ophthalmol."},{"key":"10.1016\/j.bbrc.2021.10.036_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/14712598.2018.1508443","article-title":"Corneal epithelial stem cells for corneal injury","volume":"18","author":"Bremond-Gignac","year":"2018","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.bbrc.2021.10.036_bib7","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/stem.2858","article-title":"Modeling of aniridia-related keratopathy by CRISPR\/Cas9 genome editing of human limbal epithelial cells and rescue by recombinant PAX6 protein","volume":"36","author":"Roux","year":"2018","journal-title":"Stem Cell."},{"key":"10.1016\/j.bbrc.2021.10.036_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0026-895X(25)12558-3","article-title":"Receptor-binding properties in\u00a0vitro and in\u00a0vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist","volume":"27","author":"Leysen","year":"1985","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2021.10.036_bib9","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1167\/iovs.02-1292","article-title":"Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells","volume":"44","author":"Crider","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bbrc.2021.10.036_bib10","first-page":"159","article-title":"Human corneal stem cells display functional neuronal properties","volume":"9","author":"Seigel","year":"2003","journal-title":"Mol. Vis."},{"key":"10.1016\/j.bbrc.2021.10.036_bib11","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ophtha.2012.02.043","article-title":"Pathologic epithelial and anterior corneal nerve morphology in early-stage congenital aniridic keratopathy","volume":"119","author":"Eden","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bbrc.2021.10.036_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/90042","article-title":"PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans","volume":"28","author":"Sisodiya","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2021.10.036_bib13","doi-asserted-by":"crossref","first-page":"12988","DOI":"10.1074\/jbc.M412458200","article-title":"Epidermal growth factor-induced proliferation requires down-regulation of Pax6 in corneal epithelial cells","volume":"280","author":"Li","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2021.10.036_bib14","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/mol.118.113001","article-title":"Chemoproteomic discovery of a ritanserin-targeted kinase network mediating apoptotic cell death of lung tumor cells","volume":"94","author":"Campbell","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2021.10.036_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4894","article-title":"Gene dosage manipulation alleviates manifestations of hereditary PAX6 haploinsufficiency in mice","volume":"12","author":"Rabiee","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2021.10.036_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0924-977X(91)90710-C","article-title":"Psychotropic effects of ritanserin, a selective S2 antagonist: an open study","volume":"1","author":"Strauss","year":"1991","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.bbrc.2021.10.036_bib17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"M\u00e9ndez-Mart\u00ednez","year":"2019","journal-title":"Retina"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21014443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21014443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:41:49Z","timestamp":1762094509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21014443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":17,"alternative-id":["S0006291X21014443"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.10.036","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK\/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}